A circulating miRNA assay as a first-line test for prostate cancer screening

Sharova, Evgeniya; Grassi, Angela; Marcer, Anna; Ruggero, Katia; Pinto, Francesco; Bassi, Pierfrancesco; Zanovello, Paola; Zattoni, Filiberto; D’Agostino, Donna M.; Iafrate, Massimo; Ciminale, Vincenzo

doi:10.1038/bjc.2016.151

Cited by 48 publications

(50 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our PCa patient cohort, we found that miR‐221, miR‐425, miR‐494, miR‐361 and miR‐130b were the most upregulated plasma miRNAs. With the exception of miR‐425, miR‐494 and miR‐361, the deregulation of miR‐221 and miR‐130b in the plasma of PCa patient has already been described . Agaoglu et al .…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

et al. 2017

View full text Add to dashboard Cite

The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-naïve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.

show abstract

Section: Discussionmentioning

confidence: 98%

“…In addition, Sharova et al . calculated the ratio of the plasma levels of circulating miR‐106a and miR‐130b in PCa patients, and found that it predicts the presence of localized PCa …”

Section: Discussionmentioning

confidence: 99%

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sharova et al . found that the ratios between three circulating miRNAs could better discriminate prostate cancer from benign prostate hyperplasia than prostate‐specific antigen (PSA) values in 67 patients . In a recent study, the performance of several noninvasive biomarkers (PSA, androgen receptor CAG repeat analysis and promoter methylation analysis of the genes GSTP1 and RASSF1A) was investigated in plasma from 186 men scheduled for biopsy due to elevated PSA levels and/or abnormal digital examination findings.…”

Section: Can Ctdna Be Used To Distinguish Benign From Malignant Lesions?mentioning

confidence: 99%

Cell‐free tumour DNA testing for early detection of cancer – a potential future tool

et al. 2019

View full text Add to dashboard Cite

In recent years, detection of cell‐free tumour DNA (ctDNA) or liquid biopsy has emerged as an attractive noninvasive methodology to detect cancer‐specific genetic aberrations in plasma, and numerous studies have reported on the feasibility of ctDNA in advanced cancer. In particular, ctDNA assays can capture a more ‘global’ portrait of tumour heterogeneity, monitor therapy response, and lead to early detection of resistance mutations. More recently, ctDNA analysis has also been proposed as a promising future tool for detection of early cancer and/or cancer screening. As the average proportion of mutated DNA in plasma is very low (0.4% even in advanced cancer), exceedingly sensitive techniques need to be developed. In addition, as tumours are genetically heterogeneous, any screening test needs to assay multiple genetic targets in order to increase the chances of detection. Further research on the genetic progression from normal to cancer cells and their release of ctDNA is imperative in order to avoid overtreating benign/indolent lesions, causing more harm than good by early diagnosis. More knowledge on the sources and elimination of cell‐free DNA will enable better interpretation in older individuals and those with comorbidities. In addition, as white blood cells are the major source of cell‐free DNA in plasma, it is important to distinguish acquired mutations in leukocytes (benign clonal haematopoiesis) from an upcoming haematological malignancy or other cancer. In conclusion, although many studies report encouraging results, further technical development and larger studies are warranted before applying ctDNA analysis for early cancer detection in the clinic.

show abstract

“…Deregulated miRNAs commonly occur in many cancers and different miRNAs have been proposed as promising diagnostic biomarkers in many cancers, including MM. In general miRNAs are excellent biomarkers because are stable and can be analyzed in routinely processed tissue samples (87), as well as in blood samples (88,89).…”

Section: Micrornas (Mirnas)mentioning

confidence: 99%

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Chen

Gaudino

Pass

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease.However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies. Here we review the most promising biomarkers in MM to date: mesothelin, soluble mesothelin-related peptides (SMRPs), megakaryocyte potentiating factor (MPF), Osteopontin (OPN), Fibulin-3, high mobility group B1 (HMGB1), microRNAs (miRNAs), multiplex protein signatures. The validation of these biomarkers will allow their use, alone or in combination, for monitoring individuals from cohorts at risk of MM and attaining early detection of MM that is instrumental in improving patient survival.

show abstract

A circulating miRNA assay as a first-line test for prostate cancer screening

Cited by 48 publications

References 17 publications

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

Plasma microRNA signature is associated with risk stratification in prostate cancer patients

Cell‐free tumour DNA testing for early detection of cancer – a potential future tool

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Contact Info

Product

Resources

About